More than a decade ago, the pharmaceutical landscape underwent a seismic shift when Amgen introduced Blincyto, the first bispecific antibody approved to treat a malignancy. By bridging the gap between immune cells and cancer cells, this "molecular handshake" paved the way for a new class of immunotherapy. Today, the oncology sector is poised for yet another evolutionary leap: the transition from bispecific to trispecific antibodies.
As researchers and clinicians prepare for the upcoming American Society of Hematology (ASH) meeting, the spotlight is shifting toward these three-pronged therapies. By targeting three distinct antigens simultaneously, these sophisticated molecules are designed to overcome the adaptive resistance mechanisms that tumors frequently employ to evade treatment. With major players like Johnson & Johnson (J&J) and AbbVie leading the charge, the data emerging from ASH signals a potential paradigm shift in the treatment of multiple myeloma and beyond.
The Chronology of Targeted Immunotherapy
The Bispecific Foundation (2014–2024)
The journey began in 2014, when the FDA cleared Amgen’s Blincyto for the treatment of rare forms of acute lymphoblastic leukemia. Blincyto functions by binding to CD19 on cancer cells and CD3 on T-cells, effectively "handcuffing" the killer T-cells to their targets. The success of this mechanism acted as a catalyst for a massive R&D push.
In the years following, the pharmaceutical industry saw an influx of bispecific approvals. Johnson & Johnson solidified its footprint in blood cancer with the development of Tecvayli (teclistamab) and Talvey (talquetamab). Similarly, Pfizer and AbbVie expanded the reach of these drugs into lymphoma and multiple myeloma. Amgen eventually pushed the technology into solid tumors with bispecific applications for lung cancer.
The Emergence of the Trispecific Era (2024–Present)
As clinical experience with bispecifics grew, so did the awareness of their limitations. Cancer is an evolutionary disease; as patients receive treatment, tumor cells often undergo antigen loss—essentially "hiding" the protein that the drug was designed to target.
By adding a third target, researchers believe they can build a "redundancy" into the therapy. If a cancer cell tries to downregulate one protein to escape destruction, the drug can still anchor itself to the other two targets, ensuring the T-cell remains engaged. This week’s release of abstracted data for the ASH meeting confirms that this theoretical advantage is now moving into rigorous human clinical trials.
Supporting Data: The Power of Three
The data published ahead of the ASH conference highlights several promising candidates that utilize this three-pronged approach, specifically targeting the complex landscape of multiple myeloma.
J&J’s Ramantamig
J&J is moving aggressively with its candidate, ramantamig. This molecule targets CD3 on the T-cell, alongside two proteins on the myeloma cell: BCMA and GPRC5D.
The clinical results for ramantamig are striking. In a mid-stage trial involving newly diagnosed patients eligible for bone marrow transplants, J&J utilized the drug as part of an "induction" regimen alongside standard treatments like Darzalex and Revlimid. According to the data, 100% of the 20 evaluable patients achieved "minimal residual disease (MRD) negativity" after three cycles of treatment. MRD negativity—where no detectable cancer cells remain—is considered a "gold standard" predictor for long-term survival in hematology.
AbbVie’s ABBV-2001
AbbVie is also making significant strides with ABBV-2001, a trispecific antibody licensed from Ichnos Glenmark. This drug binds to CD3, BCMA, and CD38. In Phase 1 testing focused on relapsed or refractory patients, the drug demonstrated remarkable efficacy, with 75% to 85% of participants showing a clinical response. Furthermore, of those who achieved a "complete response," roughly 83% to 88% reached MRD-negative status.
Global Innovation: Innovent and Shanghai Xianxiang
The race is not limited to Western pharmaceutical giants. Chinese biotech firms are providing some of the most compelling early data:
- Innovent Biologics: Their candidate, IBI3003, targets the same receptors as J&J’s ramantamig. In Phase 1 trials, it achieved a 77% response rate among patients receiving the optimized dosage.
- Shanghai Xianxiang Medical Technology: Their candidate, SIM0500, reached an overall response rate as high as 86% in the highest doses tested, underscoring the potential for high-potency outcomes in late-stage disease.
Implications for the Future of Cancer Care
Overcoming Tumor Heterogeneity
The most significant implication of these findings is the ability to address tumor heterogeneity. In many blood cancers, not every tumor cell expresses the same protein profile. A bispecific drug might kill 80% of the cells, but the remaining 20%—those lacking the target antigen—can continue to proliferate, leading to relapse.
By binding to three targets, trispecific antibodies theoretically cover a much larger "surface area" of the tumor. As RBC Capital Markets analysts noted in a recent client briefing, these assets represent a significant expansion of the standard-of-care portfolio, potentially turning formerly fatal relapses into manageable, long-term conditions.
Clinical and Regulatory Hurdles
Despite the excitement, the transition to trispecifics is not without challenges. The manufacturing complexity of a molecule that binds to three distinct targets is significantly higher than that of a bispecific or a standard monoclonal antibody. There are also concerns regarding toxicity; by engaging more pathways on immune cells, the risk of "cytokine release syndrome" (an inflammatory response) or neurotoxicity may increase.
Regulators will likely scrutinize the safety profiles of these drugs as closely as their efficacy. The ongoing Phase 1 and 2 trials will be critical in determining the "therapeutic window"—the delicate balance between maximizing cancer cell destruction and minimizing systemic damage to the patient.
Official Responses and Industry Outlook
The pharmaceutical industry views the ASH meeting as a watershed moment for these assets. Analysts from RBC Capital Markets have suggested that J&J’s data, in particular, provides a "strong early signal" that the company is effectively building a "moat" around its multiple myeloma franchise. By offering a portfolio that includes bispecifics (Tecvayli, Talvey) and a next-generation trispecific (ramantamig), J&J is positioning itself to lead the field through the next decade.
Similarly, the emergence of smaller, agile players like Kali Therapeutics, which is presenting preclinical research at ASH, suggests that the field is attracting a wide ecosystem of innovation. Startups are focusing on the mechanics of antibody engineering, trying to optimize the "avidity" or strength with which these drugs bind to their targets.
The Road Ahead
As we look toward the ASH meeting, the scientific community will be looking for answers to three critical questions:
- Durability: Do these high response rates hold up over 12, 24, or 36 months?
- Toxicity Management: Can clinicians mitigate side effects to allow for outpatient administration?
- Combination Therapy: How do these trispecifics interact with existing immunotherapies and chemotherapies?
If the early data from the ASH meeting holds true, we are witnessing the birth of a new modality in medicine. Trispecific antibodies represent a move away from the "one-size-fits-all" approach to cancer care, signaling a future where treatments are as complex and adaptable as the diseases they aim to eradicate. For patients with multiple myeloma and other blood cancers, this represents more than just a technological improvement; it represents a tangible increase in the odds of achieving a durable, deep, and potentially life-altering remission.
About the Author
